We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Antibiotics Could Develop From a DNA Binding Compound

By LabMedica International staff writers
Posted on 13 Jul 2009
A synthetic compound has proved surprisingly effective at binding to the DNA of bacteria, killing them on touch within two minutes. More...


Researchers at the at the University of Warwick (Coventery, United Kingdom) discovered the new compound ([Fe2L3]4+), which is composed of an iron triple helicate with three organic strands wrapped around two iron centers, thus forming a helix which looks cylindrical in shape and neatly fits within the major groove of a DNA helix. When the iron-helicate binds to this major groove, it coils the DNA so that it is no longer available to bind to anything else, and is not able to drive biological or chemical processes. A high positive charge inherent in the compound enhances its ability to bind to DNA, which is negatively charged.

The researchers initially focused on the application of this useful property for targeting the DNA of cancer cells, since it could bind to, coil up, and shut down the cancer cell's DNA, thus killing the cell or stopping it replicate. However, the research team quickly realized that it might also be a very clever way of targeting drug-resistant bacteria; since it operates by targeting DNA; the iron helicate avoids all current resistance mechanisms of multiresistant bacteria such as methillicin resistant Streptococcus aureus (MRSA). Subsequently, they found that [Fe2L3]4+ does indeed have a powerful effect on bacteria; when introduced to two test bacteria (Bacillus subtilis and Escherichia coli), it quickly bound to the bacteria's DNA and killed virtually every cell within two minutes of being introduced (though the concentration required for this is high). The study was published in the June 2009 issue of the International Journal of Antimicrobial Agents.

"We were surprised at how quickly this compound killed bacteria and these results make this compound a key lead compound for researchers working on the development of novel antibiotics to target drug resistant bacteria,” said lead author Professor Alison Rodger, Ph.D., of the department of biophysical chemistry.

The researchers will next try to understand how and why the compound can cross the bacteria cell wall and membranes. They also plan to test a wide range of compounds to search for molecules similar to the iron helicate which posses the same mechanism for action, in collaboration with researchers around the world.

Related Links:
University of Warwick




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.